Pfizer plans to manufacture 120 million courses of Paxlovid in 2022. The US govt has already ordered 20 million courses of Paxlovid at $530/each. Pfizer expects to sell $32 million worth of Covid vaccines in 2022. They sold $36.8 million of the Covid vaccine in 2021. Do the math! Analysts were “disappointed” in the recent 2022 revenue projections because Pfizer only counts Paxlovid revenue for which they already have a sales agreement. Pfizer is in negotiations with over 100 countries.$:Pfizer(PFE)$
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments
Indeed. The pills are more expensive and generate more revenue than their vaccine. $60B of pills this year. It eclipse the $34B of vaccine revenue from bith moderna and pfizer last year.